Portal Announces First Texas Investment – March Biosciences

We’re excited to announce our first Texas investment in March Biosciences. March Biosciences is a clinical-stage company in the cell therapy field focused on developing CAR-T cell strategies to address the most challenging hematological cancers. Read more about our investment in March Biosciences in Endpoints.